Mycobacterium abscessus group pulmonary disease

Predictably favorable treatment outcomes for patients with M. abscessus pulmonary disease remain elusive. New antibiotic combinations offer promise but await clinical testing in prohibitively expensive trials. Some new approaches such as phage therapy have been introduced, but so far, none are universally available or reliably effective. Clinicians and patients are left to struggle with imperfect treatment strategies in the hopes that some will emerge to justify larger treatment trials.